Gene testing for all breast cancer patients with second primary malignancy, atezolizumab for TNBC, pralsetinib for NSCLC, and more

episode

Blood & Cancer not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Songs of John Farnham: A Living Legend | Tony Cochrane (23.09.26) 7 min · 23 Sep 2026 · Whateley

Las 10 de Erazno, el Chokolatazo, Parodias, 1h 29m · 23 Sep 2026 · Erazno y La Chokolata El Podcast

Steve Hilton & Spencer Pratt: Fixing California, Cheaper Gas, Ballot Fraud & CA Republicans 55 min · 23 Sep 2026 · All-In with Chamath, Jason, Sacks & Friedberg

Optics of Alastair Clarkson's brunt sacking | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

The Eminently Sensible Phil Davis | Whateley (23.09.26) 13 min · 23 Sep 2026 · Whateley

The impact of Zak Butters' homecoming | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

Report any issue

Source

Recorded15 Sep 2020

Publisherjcsopodcast.libsyn.com ↗

Handlerec:14215287

Show notes

Hematology/Oncology News: Study supports multigene panel testing for all breast cancer patients with second primary cancers: https://bit.ly/3m6RyOGSource: https://bit.ly/2ZKXund Atezolizumab TNBC indication 'in jeopardy' because of phase 3 results: https://bit.ly/35rqzrl Alert: https://bit.ly/2Reh1HMTrial: https://bit.ly/2ZqqIqX Pralsetinib: Second drug for RET+ NSCLC approved in U.S.: https://bit.ly/3bTdGaz Unexpected results in new COVID-19 'cytokine storm' data: https://bit.ly/3k8fIGL JAMA research letter: https://bit.ly/35ubxB4 You can email the show at [email protected]

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in